Search & Filter

Edoxaban (Lixiana) provides comparable efficacy and greater safety compared to warfarin, sub-analysis data presented at the European Society of Cardiology Congress in Barcelona, Spain, has revealed.

Higher coffee consumption is associated with a lower risk of death, according to research presented at the ESC Congress. 

Marriage is a vital factor affecting the survival of patients who have had a heart attack, as well as the survival of patients with the most important risk factors, according to research presented today at ESC Congress.

Higher coffee consumption is associated with a lower risk of death, according to research presented at the ESC Congress. The observational study in nearly 20,000 participants suggests that coffee can be part of a healthy diet in healthy people.

A new analysis from the evolocumab (Repatha) cardiovascular outcomes study (FOURIER) showed a statistically significant relationship between lower achieved low-density lipoprotein cholesterol (LDL-C) levels and lower cardiovascular event rates in patients with established atherosclerotic cardiovascular disease. 

Marriage is a vital factor affecting the survival of patients who have had a heart attack, as well as the survival of patients with the most important risk factors, according to research presented today at ESC Congress.

Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with stable coronary or peripheral artery disease, according to results from the COMPASS trial presented at the European Society of Cardiology Congress in Barcelona.

New sub-analysis data demonstrating that edoxaban (Lixiana) provides comparable efficacy and greater safety compared to warfarin, across non-valvular atrial fibrillation (NVAF) patients with different stroke risk scores was presented at the European Society of Cardiology Congress in Barcelona, Spain.

Following more than two decades of research, the results of the CANTOS trial found that the IL-1β inhibitor canakinumab lowers the risk of cardiovascular disease and lung cancer risk by reducing inflammation.

The European Committee for Medicinal Products for Human Use (CHMP) has recommended approval of a label update for the oral, once-daily direct factor Xa-inhibitor edoxaban (Lixiana), to provide guidance on its use in patients undergoing transoesophageal echocardiography (TEE)-guided and delayed cardioversion.

A new imaging technique uncovers oxygen levels in prostate tumours and could lead to a non-invasive way to determine which tumours are more difficult to treat, according to a Cancer Research UK-funded study published in Theranostics.

A new study by the University of Warwick indicates that only two in three doctors who are completing their training to become GPs plan to work in NHS general practice.

One year on from the launch of the government's Childhood Obesity Plan, the OHA has issued a report card saying that, despite good progress, the government 'must try harder' to tackle the problem. 

People aged 65 years and over could receive greater influenza protection after the approval of the adjuvanted trivalent influenza vaccine (aTIV), Fluad, for the 2018/19 season.

People aged 65 years and over can now be offered greater protection from influenza infection for the 2018/19 season, thanks to the UK regulator approving the adjuvanted trivalent influenza vaccine (aTIV), Fluad.